{
      "Rank": 415,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)",
            "Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)"
      ],
      "ArmGroupInterventionName": [
            "Drug: XCEL-UMC-BETA",
            "Drug: Placebo",
            "Drug: XCEL-UMC-BETA",
            "Drug: Placebo"
      ],
      "ArmGroupLabel": [
            "XCEL-UMC-BETA/placebo",
            "Placebo/XCEL-UMC-BETA"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03003364"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo controlled, two-way crossover clinical trial in which 10 patients from 18 to 65 years of age affected with chronic traumatic spinal cord will enter the study with the objective to assess the safety and to obtain efficacy data in intrathecal administration of expanded Wharton's jelly mesenchymal stem cells."
      ],
      "BriefTitle": [
            "Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "UNKNOWN",
            "INDUSTRY",
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "Hospital de Neurorehabilitaci\u00f3 Institut Guttmann",
            "Recerca Cl\u00ednica S.L.",
            "Syntax for Science, S.L"
      ],
      "CompletionDate": [
            "February 11, 2020"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Spinal Cord Injury, Chronic"
      ],
      "ConditionAncestorId": [
            "D000013118",
            "D000002493",
            "D000009422",
            "D000020196"
      ],
      "ConditionAncestorTerm": [
            "Spinal Cord Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Trauma, Nervous System"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "BC26",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "Wounds and Injuries",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Spinal Cord Injury",
            "Injury"
      ],
      "ConditionBrowseLeafId": [
            "M15068",
            "M16837",
            "M15067",
            "M4894",
            "M21176",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Spinal Cord Injuries",
            "Wounds and Injuries",
            "Spinal Cord Diseases",
            "Central Nervous System Diseases",
            "Trauma, Nervous System",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000013119",
            "D000014947"
      ],
      "ConditionMeshTerm": [
            "Spinal Cord Injuries",
            "Wounds and Injuries"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Crossover Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo controlled, clinical trial in which 10 patients from 18 to 65 years of age affected with chronic traumatic spinal cord will enter the study with the objective to assess the safety and to obtain efficacy data in intrathecal administration (L3 level) of expanded Wharton's jelly mesenchymal stem cells. Following the administration patients will remain for 24 h at the hospital and thereafter will be discharged. For the first period, the follow-up is planned at day 7 and at 1, 3 and 6 months. At month 6, the patients will be treated in a crossover way (second period) and will follow the same schedule for the follow-up. First clinical trial evaluation will be performed at 12 month follow-up. From 12 to 18 month after the first infusion, patients will be randomized again to active treatment or placebo (double-blind) in order to assess the safety and efficacy of a second dose at 12 month follow-up. Thereafter, patients will be followed up at 24 and 36 months as part of a long-term follow-up."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nSingle spinal cord injury lesion caused by trauma\nAffected cord segments between T2 and T11, confirmed by magnetic resonance\nComplete paraplegia (ASIA A)\nChronic disease state (between 12 months and 5 years after the injury)\nPatients from 18 to 65 years of age, both sexes\nLife expectancy > 2 years\nConfidence that the patient will attend the follow-up visits.\nGiven informed consent in writing\nPatient is able to understand the study and its procedures\n\nExclusion Criteria:\n\nMechanic ventilation\nLesion affecting multiple levels\nLesion length superior to 3 spinal cord segments, assessed by magnetic resonance\nPenetrating trauma affecting the spinal cord\nPositive serology to HIV, HBV, HCV and or syphilis\nPregnant woman or without proper anticonceptive measures according to the investigator, or breath feeding\nUse of metal implants that complicates the MRI interpretation\nPlanned spinal surgery within subsequent 24 month after entering the trial\nIntrathecal medication or immunosuppressive drugs the previous 60 days.\nNeurodegenerative diseases\nSignificant abnormal laboratory tests that contraindicates patient's participation in the study.\nNeoplasia within the previous 5 years, or without complete remission\nPatient with difficulty for communicating\nParticipation in another clinical trial or treated with an investigational medicinal product the previous 60 days\nContraindication for lumbar punction\nOther pathologic conditions or circumstances that could complicate the participation of the patient in the study according to medical criteria\nThe patient does not accept to be followed-up for a period that could exceed the clinical trial length"
      ],
      "EnrollmentCount": [
            "10"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Placebo/XCEL-UMC-BETA",
            "XCEL-UMC-BETA/placebo",
            "Placebo/XCEL-UMC-BETA",
            "XCEL-UMC-BETA/placebo"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Intrathecal allogeneic cell therapy in a blinded syringe",
            "Placebo in a blinded syringe"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "XCEL-UMC-BETA",
            "Placebo"
      ],
      "InterventionOtherName": [
            "Expanded MSC from Wharton Jelly"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "February 17, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "February 13, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Banc de Sang i Teixits"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Badalona"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Spain"
      ],
      "LocationFacility": [
            "Hospital de Neurorehabilitaci\u00f3 Institut Guttmann"
      ],
      "LocationState": [
            "Barcelona"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "08916"
      ],
      "MaximumAge": [
            "65 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Banc de Sang i Teixits"
      ],
      "OrgStudyId": [
            "XCEL-SCI-01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hospital de Neurorehabilitaci\u00f3 Institut Guttmann"
      ],
      "OverallOfficialName": [
            "Joan Vidal, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "July 25, 2019"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Adverse events"
      ],
      "PrimaryOutcomeMeasure": [
            "Incidence of treatment-emergent adverse events"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months"
      ],
      "ReferenceCitation": [
            "Albu S, Kumru H, Coll R, Vives J, Vall\u00e9s M, Benito-Penalva J, Rodr\u00edguez L, Codinach M, Hern\u00e1ndez J, Navarro X, Vidal J. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146-156. doi: 10.1016/j.jcyt.2020.08.008. Epub 2020 Sep 25."
      ],
      "ReferencePMID": [
            "32981857"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "ASIA Impairment Scale",
            "Evoked potentials",
            "Evoked potentials",
            "Pain threshold perception",
            "Urodynamic testing",
            "Anorectal manometry test",
            "Numerical scale (0 to 10)",
            "Modified Ashworth scale",
            "SCIM III scale",
            "WHOQOL BREF questionnaire",
            "Qualiveen questionnaire",
            "Magnetic Resonance Imaging",
            "Chimerism in cerebrospinal fluid",
            "Antibodies anti-HLA in peripherical blood and in cerebrospinal fluid"
      ],
      "SecondaryOutcomeMeasure": [
            "Extent and severity of a patient's spinal cord injury",
            "Motor electrophysiology assessment",
            "Somatosensory electrophysiology assessment",
            "Electrical nerve stimulation on pain perception",
            "Mictional dysfunction",
            "Anal sphincter integrity",
            "Neuropathic pain",
            "Spasticity",
            "Functionality",
            "Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)",
            "Urinary disorder",
            "Size injury",
            "Presence of allogeneic cells",
            "Immunology"
      ],
      "SecondaryOutcomeTimeFrame": [
            "6 months",
            "6 month",
            "6 month",
            "6 month",
            "6 month",
            "6 month",
            "6 months",
            "6 months",
            "6 months",
            "6 months",
            "6 months",
            "12 months",
            "1 month",
            "1 months"
      ],
      "SeeAlsoLinkLabel": [
            "Blood and Tissue Bank of Catalonia",
            "Hospital de Neurorehabilitaci\u00f3 Institut Guttmann",
            "Marat\u00f3 TV3"
      ],
      "SeeAlsoLinkURL": [
            "http://bancsang.net/en_index/",
            "http://www.guttmann.com/en",
            "http://www.ccma.cat/tv3/marato/en/"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "December 27, 2016"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "February 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "December 28, 2016"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "December 14, 2016"
      ],
      "StudyFirstSubmitQCDate": [
            "December 21, 2016"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}